Pain Management Drugs Market Size & Share 2023 to 2032
Market Size by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine), Indication (Arthritic, Neuropathic, Cancer), Pain Type (Chronic, Acute), Distribution Channel (Hospital, Retail, Online).
Report ID: GMI6231
|
Published Date: July 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Pain Management Drugs Market Size
Pain Management Drugs Market size was valued to be USD 70.1 billion in 2022 and is expected to reach USD 108.9 billion in 2032 with a CAGR of 4.5% by 2032 due to the rising incidence of chronic diseases, increasing geriatric population who are more prone to chronic pain, and Favorable regulatory scenario. Also, rise in the number of patients for pain management of osteoarthritis, diabetic neuropathy and cancer.
Pain Management Drugs Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Additionally, pharmaceutical companies are investing in R&D in order to discover and develop novel pain management medications. Drug development innovation, such as the introduction of abuse-deterrent formulations and novel mechanisms of action, broadens patients' treatment options.
COVID-19 Impact
This pandemic has slowed economic development across a wide range of economies. The COVID-19 pandemic is anticipated to have an influence on the market for pain medication. During the COVID-19 pandemic, there was a major reduction in the number of elective operations. Many non-urgent procedures were rescheduled in order to prioritise resources for Covid-19 patients and lower the risk of infection spread in healthcare facilities.
However, the COVID-19 pandemic had a favorable effect on the market due to a potential link between Covid-19 and pain medications. For example, in July 2020, the National Center for Biotechnology Information reported that patients may have lower back discomfort, widespread myalgias, or headaches as early signs of Covid infection. There is growing evidence that SARS-CoV-2 can infiltrate the neurological system, especially in immune compromised patients. According to statistics from April 2022 released by PubMed, it was found that patients with chronic pain in the US and Canada saw a substantial rise in discomfort during the pandemic.
Pain Management Drugs Market Trends
The rising prevalence of chronic disorders, increasing healthcare expenditure and investments, increasing geriatric population, and rise in the number of research and development activities, are fuelling the industry development.
The increasing demand for nonsteroidal anti-inflammatory drugs (NSAIDs) and cannabinoids has gained traction in pain management. Research has suggested that cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), may have analgesic properties and can be used to alleviate chronic pain. Drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and certain antidepressant drugs have gained popularity in managing pain. In addition to this, combination of different classes of pain medications to achieve synergistic effects has gained healthcare professional’s attention. This approach can enhance pain relief while potentially reducing the required dosage of individual drugs.
Pain Management Drugs Market Analysis
Based on drug class, the pain management drugs market is classified into NSAIDS, anesthetics, anticonvulsants, antimigraine drugs, antidepressant drugs, opioids, non-narcotic analgesics, and other drugs. The opioids segment held the greatest market share of 29.4% in 2022. Opioids have a strong analgesic effect and are highly effective in providing pain relief, especially for severe pain that is not adequately controlled by other medications. Their ability to target opioid receptors in the central nervous system helps to block pain signals and alleviate discomfort.
Based on indication type, the pain management drugs market is categorized into arthritic pain, neuropathic pain, cancer pain, chronic back pain, post-operative pain, migraine, fibromyalgia, bone fracture, muscle sprain/strain, acute appendicitis, and other indications. The neuropathic segment held the largest market share of 19.7% in 2022. Neuropathic pain is a prevalent disease that affects a large number of people globally. It can be caused by a variety of underlying diseases, such as diabetic neuropathy, post-herpetic neuralgia, nerve injuries, and neuropathies linked with disorders such as multiple sclerosis.
Based on pain type, the pain management drugs market is bifurcated into chronic pain and acute pain. The chronic pain segment was anticipated to be worth USD 40.4 billion in 2022 and is expected to grow at 4.7% CAGR by 2032. Advances in drug delivery technology and formulation processes have increased the efficacy and convenience of chronic pain treatment medicines. Extended-release formulations, transdermal patches, and new delivery technologies improve pain management and patient compliance.
Based on distribution channel, the pain management drugs market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held dominant market share of around 42.6% in 2022 and is expected to grow at a significant pace of 4.4% by 2032. The demand for pain management drugs is substantial due to various acute and chronic pain conditions.
North America pain management drugs market accounted is expected to reach USD 42 billion in 2032 with a CAGR of 4.1% by 2032 attributed to the factors such as high incidence of chronic diseases, growing elderly population, and availability of well-developed healthcare infrastructure. North America focuses on technology advances in pain treatment such as novel drug delivery methods, neuromodulation devices such as spinal cord stimulators, and non-invasive treatments such as transcranial magnetic stimulation give alternative treatment choices.
Moreover, North America has stringent regulatory frameworks governing the development, approval, and marketing of pain management drugs. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and Health Canada, prioritize patient safety and efficacy. Compliance with regulatory requirements ensures high standards and quality in the industry.
Pain Management Drugs Market Share
The prominent players are
Pain Management Drugs Market Industry News:
The pain management drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Drug class
By Indication Type
By Pain Type
By Distribution Channel
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →